Up to 4 follow-up visits (after baseline) were expected for 141 LRRK2-associated parkinsonism cases; the majority completed year 4 (31 (69%) CSFasynSAA- and 78 (81%) CSFasynSAA+ cases). The gene discussed is LRRK2; the disease is Parkinson disease.